How will a new regulatory landscape impact the EU and UK pharma industries? Early 2022 will see major new clinical trial legislation come into effect, with proposals for an entirely new regulatory regime promised by the end of the year. Paul Ranson, Consultant at Morgan Lewis, reflects on this and whether the UK’s response in the light of Brexit will diverge from or align with the EU system.
The Clinical Trials Regulation
The conduct of clinical trials in the EU will be radically changed with the Clinical Trials Regulation (Regulation (EU) No 536/2014) (CTR) in force from 31 January 2022. Given the date of the implementing legislation, it is evident that this new law has been a long time coming. This is primarily due to delays in the Clinical Trial Information System (CTIS) becoming fully functional, which was originally expected in September 2018 but had been postponed for various reasons including the disruption caused by Brexit and COVID-19. The CTIS will contain the centralised EU portal and database for clinical trials envisaged by the regulation.
The CTR is intended to harmonise procedures for carrying out clinical trials across the EU and to simplify the clinical trial approval process by submission through the database and portal”
The CTR replaces the Clinical Trials Directive 2001/20/EC (CTD) and will, through the CTIS, streamline the registration, assessment and supervision processes for EU clinical trials. The CTD allowed for national rules around the assessment of the conduct of trials with such rules varying between member states.
The CTR is intended to harmonise procedures for carrying out clinical trials across the EU and to simplify the clinical trial approval process by submission through the database and portal. Opinions must now be issued within new legally set timelines with the role of the ethics committees to continue.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
Alongside the submission of a single CT dossier through the portal, the improved assessment process should make it easier for pharmaceutical companies to conduct multinational clinical trials by ensuring efficiency of resources and expediting approval timelines. Unless confidentiality is justified for the protection of commercially confidential information, personal data or member state supervision, the information submitted to the portal and database will be published, facilitating full transparency of ongoing trials and their results to the public.
The aim is to create a trial regime that is “favourable to conducting clinical trials in the EU, with the highest standards of safety for participants and increased transparency of trial information”.
Informed consent will be a significant issue in clinical trials. Trial sponsors will need to review their consent policies against the CTR, reconcile them with their data protection policies and ensure that both also meet the requirements of the General Data Protection Regulation 2016/679 (GDPR). The extent of the GDPR’s reach to co-sponsors, sites and contract research organisations (CROs) must also be factored in alongside the enhanced rights of data subjects to withdraw consent at any time, request deletion of data and the right “to be forgotten”.
Other aspects of the CTR include more detailed safety provision assessments, new indemnity provisions and a category for low interventional trials. Definition of ultra-rare diseases as a political concept will also be introduced for the first time at EU level.
The Commission Delegated Regulation (EU) 2017/1569 of 23 May 2017, supplementing Regulation (EU) No 536/2014 of the European Parliament and of the Council, will apply to all clinical trials authorised based on the CTR. It specifies principles and guidelines for good manufacturing practice (GMP) for investigational medicinal products for human use and arrangements for inspections.
There are also transitional measures. Prior to 31 January 2023, all new clinical trial applications can be submitted under either the CTD or the CTR, but thereafter new clinical trial applications must be submitted under the CTR. Until 31 January 2025, ongoing CTD-authorised clinical trials can either remain under the CTD or can transition to the CTR, but thereafter all ongoing clinical trials must have transitioned to CTR and the CTIS.
The UK Government has stated that it will align “where possible” with the CTR. Clause 4(1)(a) of the UK Medicines and Medical Devices Bill is described as providing “the means for provision to be made which is corresponding or similar to the EU Clinical Trials Regulations, if the Government were to choose to do so”. On 17 January 2022 the UK Medicines and Healthcare products Regulatory Agency (MHRA) consulted on proposals for a more streamlined and flexible regulatory regime for clinical trials in the UK that are based on the CTR.
EU pharmaceutical strategy
It was perceived that the current legislative code for medicines (Directive 2001/20/EC) was showing its age in respect of weaknesses in the areas of research, production and distribution of medicines in Europe (exposed by the COVID-19 pandemic); with access to affordable medicines identified as a key challenge. Accordingly, in November 2020, the European Commission (EC) adopted its roadmap document, the Pharmaceutical Strategy for Europe, and in September 2021 issued a public consultation on the revision of the EU’s pharmaceutical legislation. The EC intends to implement certain “flagship actions” including a revision of the general pharmaceutical regulatory regime envisaged for end of 2022.
The key priority areas for consideration and reform are as follows:
The performance and adequacy of the current legislation
Unmet medical needs – with a definition or set of principles for “unmet medical needs” under discussion
Incentives for innovation, including in the area of unmet needs and considering regulatory data and market exclusivity
Antimicrobial resistance – measures to support innovation of antibiotic development
Future-proofing the regulatory framework for novel products
Improved patient access to and affordability of medicines in the EU
Competitiveness of the European markets to ensure affordable medicines, including considering measures to support patients’ access to affordable medicines
Encouraging the repurposing of off‑patent medicines
Ensuring security of supply of medicinal products in the EU
Ensuring high quality manufacture and distribution in the EU including consideration of the need to strengthen or adapting GMPs to reflect new manufacturing methodologies
Environmental challenges.
Medicines and Healthcare products Regulatory Agency
Since 1 January 2021, the MHRA has been the UK’s standalone medicines regulator. As a result of the Northern Ireland protocol, different rules currently apply in Northern Ireland to those in Great Britain (GB); broadly, Northern Ireland will continue to follow the EU regulatory regime. Notwithstanding the nominal expiry of the arrangement on 1 January 2022, there is some optimism on achieving a deal whereby the EU would permit UK-approved medicines to enter Northern Ireland, although to date this proposal has yet to be finalised.
The MHRA published a raft of guidance on how various aspects of the UK medicines regulatory regime should henceforth operate in England, Wales and Scotland (together, GB) and in Northern Ireland following the expiry of the Brexit transition period on 31 December 2020.
Since the expiry of the transition period, existing EU legislation was automatically incorporated into UK domestic legislation through the Human Medicines Regulations (Amendment etc) (EU Exit) Regulations 2019, but EU legislation that took effect after the expiry of the transition period (such as the CTR) has not been applied in the UK.
The MHRA has not yet reacted in light of the EU Pharmaceutical Strategy, and it remains to be seen what divergence/alignment position the UK Government of the day will take to the proposed EU legislation. However, with reports for potential staff cuts of 20 percent of the MHRA’s 1,200-strong workforce due to post-Brexit revenue losses and other challenges, and the MHRA’s continuing ambition to remain a world-class regulator, it seems inevitable that there will be changes. These are reported to include eliminating work that “does not add value” and creating new pathways to attract sponsors of innovative medicines, joining international work-sharing schemes to speed up drug approvals, and streamlining the evaluation of clinical trials.
Reimbursement
In December 2021, the Regulation on Health Technology Assessment (HTA Regulation) was adopted, billed as a specific deliverable under the EU Pharmaceutical Strategy. HTA, commonly described as “value-based assessment” or “value‑based pricing”, is used to make pricing and reimbursement decisions in most member states. It involves the use of economic techniques to assess the value of new and existing medicines, whereby a drug’s cost-effectiveness against its comparator will determine the price premium over its existing product and, therefore, the medicine’s price.
2022 will mark a step change in the regulatory outlook for the EU and regulatory developments will lead to market change”
With very limited previous harmonisation between the HTA bodies in Europe, it was hoped by the industry that the regulation would allow for joint assessment of relative effectiveness on the basis of clinical evidence and that joint early scientific dialogue could take place with HTA agencies, thus avoiding duplication of their efforts and differing outcomes. However, the need for compromise in the face of member state resistance led to considerable watering down of the original principles, whereby member states can still decide on a case-by-case basis if and how they commit themselves to use jointly conducted clinical assessments.
While it came into effect on 1 January 2022, the HTA Regulation provides for a delayed application of three years, during which time the EC will set up a Coordination Group of Member States, establish the Stakeholder Network, adopt the necessary implementing and delegated acts, and facilitate the development of methodology for joint HTA work by the Coordination Group.
Given that the HTA Regulation came into force after 1 January 2021, it will not apply in the UK and hence it is not envisaged that the UK HTA body, the National Institute for Health and Care Excellence (NICE), will be impacted.
Conclusion
2022 will mark a step change in the regulatory outlook for the EU and regulatory developments will lead to market change. While the focus on medicines for unmet needs is laudable, the industry may well be concerned over the EC’s efforts to encourage competition through the promotion of generics and pricing scrutiny. A promised review of R&D incentives, such as market exclusivity for orphan medicines, will also be closely watched. The EC will need to balance innovation with affordability and the UK Government, seeking to retain the UK’s own attractiveness as a market, will inevitably be watching such Commission decisions when deciding whether to diverge or align with the EU.
Paul Ranson is a Consultant in London at global law firm, Morgan Lewis. He focuses on the regulatory and commercial needs of the pharmaceutical, biotechnology and medical devices sectors. Paul’s regulatory experience covers both marketing authorisation‑related matters and market access, pricing and reimbursement issues. His commercial work is concentrated on transactions with a high degree of industry specificity including collaborations and outsourcing transactions.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.